Market Overview

Research and Markets: Niche Markets and Rare Diseases: Idiopathic Pulmonary Fibrosis


Research and Markets ( has announced the addition of Decision Resources, Inc's new report "Niche Markets and Rare Diseases: Idiopathic Pulmonary Fibrosis" to their offering.

Idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases (ILDs) and is the most prevalent pulmonary fibrotic disease. IPF is associated with high morbidity and mortality; mean survival following diagnosis is two years. Until 2011, no drugs were licensed for IPF in either the United States or Europe; pirfenidone (InterMune's Esbriet) launched in Germany in September 2011. In addition, no disease-modifying drug therapies are strongly recommended in the 2011 guidelines on IPF management. Guidelines recommend IPF cases be considered for lung transplant, given the absence of any drug therapies to improve their condition. Several pharmaceutical developers are investing in developing treatments for IPF; five new agents are poised for approval for use in IPF over the 2010-2020 forecast period.

Key Topics Covered:

Executive Summary.

Key Parameters of the Idiopathic Pulmonary Fibrosis Market

Market Share of Key Drug Classes, 2015 and 2020



Drug Development Activity

What Do The Experts Say?

Key Challenges & Opportunities

Clinical Context

Disease Burden


Disease Progression

Disease Staging


The Role of Inflammation

Physician Opinion on the Role of Inflammation

Signaling Molecules as Drug Targets

Recent Failures in Drug Trials

Patient Populations

Diagnosed Prevalent Cases

Diagnosed Prevalent Cases, by Age and Severity

Patient Population Methods

Drug-Treated Population

Current Therapies and Medical Practice

Diagnostic Criteria

Diagnostic Tests

Trends in Diagnosis

Diagnosis and Referral Patterns: United States

and much more...

For more information visit

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals

View Comments and Join the Discussion!